Sumitomo Chemical Files Suit Against Pfizer for Amlodipine Besilate.Tokyo, Japan, Nov 2, 2005 - (JCNN JCNN Japan Corporate News Network ) - Sumitomo Chemical announced on November 1 that it and its subsidiary Dainippon Sumitomo Pharma have jointly filed suit against Pfizer in the Tokyo District Court Tokyo District Court (東京地方裁判所; Tōkyō Chihō Saibansho) is a district court in Kasumigaseki, Chiyoda, Tokyo, Japan. See also
In response to a preliminary injunction A temporary order made by a court at the request of one party that prevents the other party from pursuing a particular course of conduct until the conclusion of a trial on the merits. A preliminary injunction is regarded as extraordinary relief. petition filed by Pfizer in October, the two companies seek a declaratory judgment that their right to manufacture and sell amoldipine besilate remains valid. Amoldipine besilate is a hypertension drug discovered by Pfizer. Since 1991, Pfizer and Sumitomo Pharamceuticals, one of the two predecessor companies of Dainippon Sumitomo Pharma, have entered into a licensing agreement for amoldipine bestilate. Sumitomo Pharmaceuticals has been marketing the agent under the trade name of Amoldin since then. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion